Education
About Us
Working with TipRanks
Follow Us
Atricure (ATRC)
NASDAQ:ATRC
Earnings Data
Report Date
Aug 05, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.17Last Year’s EPS
-0.17Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Date:Apr 29, 2025
|% Change Since: -6.75%
|Next Earnings Date:Aug 05, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a strong quarter for AtriCure with significant revenue growth and profitability improvements, driven by successful product launches and franchise performances. However, challenges in the MIS ablation sector and increased operating expenses present ongoing concerns.Company Guidance
During AtriCure's First Quarter 2025 earnings call, the company reported a total revenue of $123.6 million, representing a 13.6% increase from the previous year, with U.S. revenue growth of 12.1% and international revenue growth of 20.8%. The company's appendage management revenue rose by 19%, driven by a strong 23% growth in open AtriClip devices, while open ablation product sales increased 13.7%, bolstered by the EnCompass clamp's success. The pain management franchise also saw significant acceleration, growing by 39%, thanks to the rapid adoption of cryoSPHERE MAX and cryoSPHERE+ probes. Adjusted EBITDA for the quarter was $8.8 million, a notable increase from $2.8 million in the same period of 2024. AtriCure maintained its full-year revenue guidance of $517 million to $527 million, with expectations for double-digit revenue growth and improved profitability.Record Revenue and Growth
Total revenue for the first quarter of 2025 was $124 million, representing a 14% growth compared to the first quarter of 2024.
Significant Increase in Profitability
Adjusted EBITDA for the first quarter was $9 million, an improvement of more than 200% from the first quarter of 2024.
Strong Performance in Appendage Management
Worldwide appendage management revenue grew 19%, with 23% growth in open AtriClip devices and 7% growth in MIS appendage management devices.
Successful Product Launches
The AtriClip Flex Mini and Pro Mini devices received positive feedback, contributing significantly to the revenue of the appendage management franchise.
Pain Management Franchise Growth
The pain management franchise saw an acceleration in growth to 39% in the first quarter, driven by the adoption of cryoSPHERE MAX and cryoSPHERE+ probes.
International Revenue Growth
International revenue increased by 20.8% on a reported basis and 23.9% on a constant currency basis compared to the first quarter of 2024.
ATRC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ATRC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 29, 2025 | $34.65 | $29.91 | -13.68% |
Feb 12, 2025 | $42.36 | $39.59 | -6.54% |
Oct 29, 2024 | $29.43 | $34.83 | +18.35% |
Jul 30, 2024 | $22.00 | $21.57 | -1.95% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Atricure (ATRC) report earnings?
Atricure (ATRC) is schdueled to report earning on Aug 05, 2025, TBA Not Confirmed.
What is Atricure (ATRC) earnings time?
Atricure (ATRC) earnings time is at Aug 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ATRC EPS forecast?
ATRC EPS forecast for the fiscal quarter 2025 (Q2) is -0.17.